Showing 1241-1250 of 1281 results for "".
- Can Turning Off a Mutation Causing Wrinkling and Hair Loss Reverse the Processes? New Mouse Model Says Yeshttps://practicaldermatology.com/news/can-turning-off-a-mutation-causing-wrinkling-and-hair-loss-reverse-the-processes-new-mouse-model-says-yes/2457680/A new mouse model may one day allow scientists to reverse age-associated wrinkles and hair loss. When a mutation leading to mitochondrial dysfunction is induced, the mouse develops wrinkled skin and extensive, visible hair loss in a matter of weeks, but when the mitochondrial function is
- Dermatologists, Skin Cancer Survivors Tell "Skin Cancers, Take a Hike!"https://practicaldermatology.com/news/dermatologists-skin-cancer-survivors-tell-skin-cancers-take-a-hike/2457695/To help raise awareness of skin cancer prevention and detection, 12 dermatologists, skin cancer survivors, and their family and friends will tell “Skin Cancer, Take a Hike!” during a four-day trek through remote Alaska. Starting Sunday, July 15, the hikers will trek more than 20 miles
- New PSA From American Academy of Dermatology Highlights Dangers of Tanninghttps://practicaldermatology.com/news/new-psa-from-american-academy-of-dermatology-highlights-dangers-of-tanning/2457753/As Memorial Day signals the unofficial start of summer, many teen girls will be eager to get out of school and spend time outside— and some may want to get a tan. But a new public service advertisement from the American Academy of Dermatology encourages those who are thinking of tanning to
- Daily Facial Exercises Help Women to Look Three Years Younger in 20 Weekshttps://practicaldermatology.com/news/daily-facial-exercises-help-women-to-look-three-years-younger-in-20-weeks/2457938/A 30-minute daily or alternate-day facial exercise program sustained over 20 weeks improved the facial appearance of middle-aged women, resulting in a younger appearance with fuller upper and lower cheeks, reports a new Northwestern Medicine study. This is the first scientific study to te
- FDA Accepts Aclaris Therapeutics' NDA for Topical Treatment of Seborrheic Keratosishttps://practicaldermatology.com/news/fda-accepts-aclaris-therapeutics-nda-for-topical-treatment-of-seborrheic-keratosis/2458188/The FDA has accepted Aclaris Therapeutics' New Drug Application (NDA) for A-101 40% topical solution, an investigational drug for the potential treatment of seborrheic keratosis (SK). The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to
- FDA Approves RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For Persistent Facial Erythema Associated With Rosaceahttps://practicaldermatology.com/news/fda-approves-rhofade-oxymetazoline-hydrochloride-cream-1-for-persistent-facial-erythema-associated-with-rosacea/2458315/The FDA has approved Allergan's RHOFADE™ cream for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29. Among the estimated 16 million aAmericans
- 8th Annual CSF Meeting Kicks Offhttps://practicaldermatology.com/news/8th-annual-csf-meeting-kicks-off/2458356/The Cosmetic Surgery Forum (CSF), now in its eighth year, was founded by NE-based dermatologist Joel Schlessinger, MD. CSF is a three-day multi-specialty educational symposium that covers the latest research, treatment and techniques in dermatology and cosmetic surgery. Unlike other meetings, res
- Kate Bosworth Partners with Allergan for ACZONE® Gel, 7.5% Launchhttps://practicaldermatology.com/news/kate-bosworth-partners-with-allergan-for-aczone-gel-75-launch/2458540/Actress, producer and model Kate Bosworth is the new face of Allergan plc’s ACZONE® (dapsone) Gel, 7.5%. ACZONE® Gel, 7.5% is a once-a-day prescription topical treatment for acne in patients 12 years of age and older. It was approved
- BioPharmX Reports Full Patient Enrollment in Phase 2a Study of BPX-01https://practicaldermatology.com/news/biopharmx-reports-full-patient-enrollment-in-phase-2a-study-of-bpx-01/2458592/BioPharmX Corporation has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01. The Phase 2a study will assess the safety of BPX-01 in 30 patients randomized to 30 days of treatment with either BPX-01 or a placebo. The endpoints of this study include red
- Lumenis Supports the Launch of Restoring Heroes Foundation for Scar Patientshttps://practicaldermatology.com/news/lumenis-launches-restoring-heroes-foundation-for-scar-patients/2458658/Kim Phuc, the young girl who was immortalized in a photograph taken during the 1972 Napalm bombing, has come a long way since that fateful day. When the photo was taken, she was running away from her village, naked, after her clothing had been burnt off. South Vietnamese plane